Medtronic MDT
NYSE · Electromedical & Electrotherapeutic Apparatus · $128.9BData provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
2 stories have a settled next close so far (2 on the Wire). The record starts speaking at three.
The numbers
fiscal 2026, as filed with the SEC · 66-metric EOD snapshot via DatabentoOperating leverage — margins
| Line Item (USD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $31.7B | $31.2B | $32.4B | $33.5B | $36.4B | +8.4% | +3.5% | |
| Cost of Revenue (COGS) | $10.1B | $10.7B | $11.2B | $11.6B | $12.7B | +9.4% | +5.8% | |
| Selling, General & Admin (SG&A) | $10.3B | $10.4B | $10.7B | $10.8B | $11.8B | +8.6% | +3.4% | |
| Operating Income (EBIT) | $5.8B | $5.5B | $5.1B | $6.0B | $6.5B | +8.6% | +3.0% | |
| Interest Expense | $553.0M | $636.0M | $719.0M | $729.0M | $715.0M | −1.9% | +6.6% | |
| Income Tax Expense | $456.0M | $1.6B | $1.1B | $936.0M | $1.3B | +38.8% | +29.9% | |
| GAAP Net Income | $5,039 | $3,758 | $3,676 | $4,662 | $4,801 | +3.0% | −1.2% | |
| Diluted EPS | $3.73 | $2.82 | $2.76 | $3.61 | $3.73 | +3.3% | +0.0% | |
| Diluted Shares | 1.35B | 1.33B | 1.33B | 1.29B | 1.29B | −0.1% | −1.2% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $3.7B | $1.5B | $1.3B | $2.2B | $1.9B | −12.1% | −14.9% | |
| Inventory | $4.6B | $5.3B | $5.2B | $5.5B | $6.0B | +8.7% | +6.6% | |
| Total Current Assets | $23.1B | $21.7B | $21.9B | $23.8B | $24.8B | +4.1% | +1.8% | |
| Total Assets | $91.0B | $90.9B | $90.0B | $91.7B | $93.0B | +1.5% | +0.6% | |
| Total Current Liabilities | $12.4B | $9.1B | $10.8B | $12.9B | $11.7B | −9.5% | −1.5% | |
| Total Debt (Short + Long Term) | $25.9B | $22.2B | $23.2B | $25.0B | $23.9B | −4.3% | −1.9% | |
| Total Liabilities | $38.3B | $39.3B | $39.6B | $43.4B | $43.0B | −1.1% | +2.9% | |
| Stockholders' Equity | $52.7B | $51.7B | $50.4B | $48.3B | $50.1B | +3.8% | −1.3% | |
| Net Cash / (Net Debt) | $-22.2B | $-20.6B | $-21.9B | $-22.8B | $-22.0B | +3.6% | — | |
| Invested Capital | $74.9B | $72.3B | $72.4B | $71.1B | $72.1B | +1.4% | −1.0% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $7.3B | $6.0B | $6.8B | $7.0B | $7.3B | +4.1% | −0.1% | |
| Depreciation & Amortization (D&A) | $2.7B | $2.7B | $2.6B | $2.9B | $3.0B | +3.4% | +2.2% | |
| Stock-Based Compensation (SBC) | $359.0M | $355.0M | $393.0M | $429.0M | $457.0M | +6.5% | +6.2% | |
| Capital Expenditures (CapEx) | $1.4B | $1.5B | $1.6B | $1.9B | $1.9B | +2.4% | +8.6% | |
| Free Cash Flow (FCF) | $6.0B | $4.6B | $5.2B | $5.2B | $5.4B | +4.6% | −2.4% | |
| True FCF (ex-SBC Owner Cash) | $5.6B | $4.2B | $4.8B | $4.8B | $5.0B | +4.5% | −3.0% | |
| Share Repurchases (Buybacks) | $2.5B | $645.0M | $2.1B | $3.2B | $1.0B | −68.0% | −20.1% | |
| Dividends Paid | $3.4B | $3.6B | $3.7B | $3.6B | $3.6B | +1.4% | +1.8% | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.